Page last updated: 2024-12-11
oxi 4503
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
Oxi 4503: diphosphate prodrug of cambretastatin A1 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 6918546 |
CHEMBL ID | 1205402 |
SCHEMBL ID | 12677563 |
MeSH ID | M0438341 |
Synonyms (22)
Synonym |
---|
oxi-4503 |
ca1p |
[3-methoxy-2-phosphonooxy-6-[(z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl] dihydrogen phosphate |
CHEMBL1205402 |
oxi4503 |
oxi 4503 |
unii-jh6z94glud |
jh6z94glud , |
combretastatin a1 diphosphate |
1,2-benzenediol, 3-methoxy-6-((1z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, 1,2-bis(dihydrogen phosphate) |
combretastatin a-1 bis(phosphate) |
288847-35-8 |
combretastatin a1 diphosphate [who-dd] |
DB05143 |
SCHEMBL12677563 |
Q27095572 |
1,2-benzenediol,3-methoxy-6-[(1z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-,1,2-bis(dihydrogen phosphate) |
1,2-benzenediol, 3-methoxy-6-[(1z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, 1,2-bis(dihydrogen phosphate) |
HY-16147 |
CS-0006163 |
combretastatin a1 phosphate |
(z)-3-methoxy-6-(3,4,5-trimethoxystyryl)-1,2-phenylene bis(dihydrogen phosphate) |
Research Excerpts
Pharmacokinetics
Excerpt | Reference | Relevance |
---|---|---|
"We have shown for the first time that PAI can observe the pharmacodynamic response of tumor vasculature to drug treatment both longitudinally and at different dose levels." | ( Longitudinal Photoacoustic Imaging of the Pharmacodynamic Effect of Vascular Targeted Therapy on Tumors. Beard, P; Johnson, SP; Lythgoe, MF; Ogunlade, O; Pedley, RB, 2019) | 0.51 |
Compound-Compound Interactions
Excerpt | Reference | Relevance |
---|---|---|
"This pre-clinical study was designed to investigate the effect of various vascular disrupting agents (VDAs) that have undergone or are in clinical evaluation, had on the oxygenation status of tumours and what effects that could have on the combination with radiation." | ( Induction of hypoxia by vascular disrupting agents and the significance for their combination with radiation therapy. Busk, M; Horsman, MR; Iversen, AB, 2013) | 0.39 |
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" In addition, the effects of continuous, daily and intermittent dosing (1-5 mg/kg) on tumor necrosis and growth were studied by quantitative histological and stereological analysis." | ( Vascular targeting agent Oxi4503 inhibits tumor growth in a colorectal liver metastases model. Chan, L; Christophi, C; Malcontenti-Wilson, C; Muralidharan, V; Nikfarjam, M, 2008) | 0.35 |
" Subcutaneous continuous dosing infusion with Oxi4503 at 1 mg/kg/day reduced tumor growth compared to the controls, but was associated with marked systemic toxicity." | ( Vascular targeting agent Oxi4503 inhibits tumor growth in a colorectal liver metastases model. Chan, L; Christophi, C; Malcontenti-Wilson, C; Muralidharan, V; Nikfarjam, M, 2008) | 0.35 |
" Intermittent dosing with Oxi4503 produced the maximum reduction in tumor growth, minimal toxicity, and a significant improvement in survival." | ( Vascular targeting agent Oxi4503 inhibits tumor growth in a colorectal liver metastases model. Chan, L; Christophi, C; Malcontenti-Wilson, C; Muralidharan, V; Nikfarjam, M, 2008) | 0.35 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (34)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 12 (35.29) | 29.6817 |
2010's | 20 (58.82) | 24.3611 |
2020's | 2 (5.88) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 18.44
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (18.44) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 4 (10.53%) | 5.53% |
Reviews | 3 (7.89%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 31 (81.58%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |